NO20075825L - Fremgangsmater og preparater til modulering og pavisning av WISP-aktivitet - Google Patents
Fremgangsmater og preparater til modulering og pavisning av WISP-aktivitetInfo
- Publication number
- NO20075825L NO20075825L NO20075825A NO20075825A NO20075825L NO 20075825 L NO20075825 L NO 20075825L NO 20075825 A NO20075825 A NO 20075825A NO 20075825 A NO20075825 A NO 20075825A NO 20075825 L NO20075825 L NO 20075825L
- Authority
- NO
- Norway
- Prior art keywords
- wisp
- modulating
- methods
- demonstrating
- preparations
- Prior art date
Links
- 230000000694 effects Effects 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 101100014709 Drosophila melanogaster wisp gene Proteins 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- 101710137353 CCN family member 4 Proteins 0.000 abstract 2
- 102100031173 CCN family member 4 Human genes 0.000 abstract 2
- 101000777560 Homo sapiens CCN family member 4 Proteins 0.000 abstract 2
- 210000004962 mammalian cell Anatomy 0.000 abstract 2
- 102100032912 CD44 antigen Human genes 0.000 abstract 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 abstract 1
- 102100027735 Hyaluronan mediated motility receptor Human genes 0.000 abstract 1
- 102100026849 Lymphatic vessel endothelial hyaluronic acid receptor 1 Human genes 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 108010003425 hyaluronan-mediated motility receptor Proteins 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 238000011065 in-situ storage Methods 0.000 abstract 1
- 230000006698 induction Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/105,876 US7455834B2 (en) | 2002-06-29 | 2005-04-14 | Methods and compositions for modulating and detecting WISP activity |
| PCT/US2006/014008 WO2006113402A1 (en) | 2005-04-14 | 2006-04-13 | Methods and compositions for modulating and detecting wisp activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20075825L true NO20075825L (no) | 2008-01-11 |
Family
ID=36809580
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20075825A NO20075825L (no) | 2005-04-14 | 2007-11-13 | Fremgangsmater og preparater til modulering og pavisning av WISP-aktivitet |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US7455834B2 (enExample) |
| EP (1) | EP1869086B1 (enExample) |
| JP (1) | JP4979684B2 (enExample) |
| KR (1) | KR101320261B1 (enExample) |
| CN (1) | CN101198623B (enExample) |
| AU (1) | AU2006236649B2 (enExample) |
| BR (1) | BRPI0612184A8 (enExample) |
| CA (1) | CA2604933C (enExample) |
| ES (1) | ES2388993T3 (enExample) |
| IL (1) | IL186095A (enExample) |
| MX (1) | MX2007012798A (enExample) |
| NO (1) | NO20075825L (enExample) |
| NZ (1) | NZ561709A (enExample) |
| RU (1) | RU2412201C2 (enExample) |
| WO (1) | WO2006113402A1 (enExample) |
| ZA (1) | ZA200708738B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7455834B2 (en) * | 2002-06-29 | 2008-11-25 | Genentech, Inc. | Methods and compositions for modulating and detecting WISP activity |
| BR112014019741A2 (pt) | 2012-02-11 | 2020-12-22 | Genentech, Inc | Usos de um antagonista da via wnt, uso de uma terapia anticâncer, método de identificação de um indivíduo com câncer, métodos para prever, método de inibição da proliferação de uma célula de câncer, uso de um antagonista da translocação de r-spondina e antagonista da translocação de r-spondina isolado |
| US20160279269A1 (en) * | 2013-03-27 | 2016-09-29 | Ge Healthcare As | Method and reagent for preparing a diagnostic composition |
| US10272154B2 (en) | 2014-04-15 | 2019-04-30 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind WISP1 |
| KR102011366B1 (ko) * | 2016-11-17 | 2019-10-14 | 연세대학교 산학협력단 | 암 전이 억제제의 스크리닝 방법 |
| CN112118857A (zh) * | 2018-05-17 | 2020-12-22 | 株式会社橄榄生物科技 | 用于预防或治疗视网膜疾病的包含ccn5作为活性成分的药物组合物 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5206161A (en) | 1991-02-01 | 1993-04-27 | Genentech, Inc. | Human plasma carboxypeptidase B |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| WO1999021998A1 (en) | 1997-10-29 | 1999-05-06 | Genentech, Inc. | Wnt-1 induced secreted polypeptides: wisp-1, -2 and -3 |
| CA2479498A1 (en) | 1999-03-08 | 2001-07-26 | Genentech, Inc. | Compositions and methods for the treatment of tumor |
| DE60333669D1 (de) | 2002-06-29 | 2010-09-16 | Genentech Inc | Verfahren und zusammensetzungen zur modulation und zum nachweis von wisp-aktivität |
| US7455834B2 (en) * | 2002-06-29 | 2008-11-25 | Genentech, Inc. | Methods and compositions for modulating and detecting WISP activity |
| WO2005025603A2 (en) | 2003-09-11 | 2005-03-24 | Genentech, Inc. | Methods of using wisp antagonists |
-
2005
- 2005-04-14 US US11/105,876 patent/US7455834B2/en not_active Expired - Lifetime
-
2006
- 2006-04-13 NZ NZ561709A patent/NZ561709A/en not_active IP Right Cessation
- 2006-04-13 WO PCT/US2006/014008 patent/WO2006113402A1/en not_active Ceased
- 2006-04-13 RU RU2007142005/10A patent/RU2412201C2/ru not_active IP Right Cessation
- 2006-04-13 EP EP06750127A patent/EP1869086B1/en active Active
- 2006-04-13 KR KR1020077023542A patent/KR101320261B1/ko not_active Expired - Fee Related
- 2006-04-13 MX MX2007012798A patent/MX2007012798A/es active IP Right Grant
- 2006-04-13 BR BRPI0612184A patent/BRPI0612184A8/pt active Search and Examination
- 2006-04-13 AU AU2006236649A patent/AU2006236649B2/en not_active Ceased
- 2006-04-13 JP JP2008506722A patent/JP4979684B2/ja active Active
- 2006-04-13 CA CA2604933A patent/CA2604933C/en not_active Expired - Fee Related
- 2006-04-13 ES ES06750127T patent/ES2388993T3/es active Active
- 2006-04-13 CN CN2006800215473A patent/CN101198623B/zh active Active
- 2006-04-13 ZA ZA200708738A patent/ZA200708738B/xx unknown
-
2007
- 2007-09-20 IL IL186095A patent/IL186095A/en not_active IP Right Cessation
- 2007-11-13 NO NO20075825A patent/NO20075825L/no not_active Application Discontinuation
-
2008
- 2008-10-20 US US12/254,649 patent/US7732567B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN101198623B (zh) | 2013-06-12 |
| AU2006236649A2 (en) | 2008-07-24 |
| KR20080003344A (ko) | 2008-01-07 |
| NZ561709A (en) | 2009-12-24 |
| JP2008537958A (ja) | 2008-10-02 |
| AU2006236649A1 (en) | 2006-10-26 |
| RU2412201C2 (ru) | 2011-02-20 |
| CA2604933A1 (en) | 2006-10-26 |
| AU2006236649B2 (en) | 2012-03-29 |
| US7732567B2 (en) | 2010-06-08 |
| WO2006113402A1 (en) | 2006-10-26 |
| MX2007012798A (es) | 2007-11-20 |
| HK1112470A1 (en) | 2008-09-05 |
| EP1869086A1 (en) | 2007-12-26 |
| CN101198623A (zh) | 2008-06-11 |
| US20060147453A1 (en) | 2006-07-06 |
| US7455834B2 (en) | 2008-11-25 |
| ES2388993T3 (es) | 2012-10-22 |
| RU2007142005A (ru) | 2009-05-20 |
| IL186095A0 (en) | 2008-01-20 |
| BRPI0612184A8 (pt) | 2017-12-26 |
| JP4979684B2 (ja) | 2012-07-18 |
| EP1869086B1 (en) | 2012-07-18 |
| KR101320261B1 (ko) | 2013-10-22 |
| IL186095A (en) | 2012-10-31 |
| CA2604933C (en) | 2014-07-08 |
| ZA200708738B (en) | 2009-01-28 |
| BRPI0612184A2 (pt) | 2011-12-20 |
| US20090148448A1 (en) | 2009-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Morris et al. | The host response to naturally-derived extracellular matrix biomaterials | |
| NO20075825L (no) | Fremgangsmater og preparater til modulering og pavisning av WISP-aktivitet | |
| BR112022027096A2 (pt) | Composições e métodos relacionados a agentes terapêuticos ativáveis | |
| MX389347B (es) | Prevención de reducción de enlaces de disulfuro durante la producción recombinante de polipéptidos. | |
| DK2016102T3 (da) | Kimære T-cellereceptorer og tilhørende materialer og fremgangsmåder til anvendelse | |
| EP2352523A4 (en) | IMPROVED ANTI-CD19 ANTIBODIES | |
| WO2004013180A3 (en) | Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof | |
| PE20091931A1 (es) | Proteinas de dominio de armazon basadas en fibronectina multivalentes | |
| IN2012DN02764A (enExample) | ||
| WO2017201432A3 (en) | Tethered interleukin-2 to its receptor il-2rbeta, a platform to enhance natural killer and regulatory t cell activity | |
| WO2020023888A3 (en) | Compositions and methods for tcr reprogramming using target specific fusion proteins | |
| IN2012DN02981A (enExample) | ||
| EA200701211A1 (ru) | Полипептиды, которые связываются с br3, и их применение | |
| NO20064134L (no) | Modifiserte bouganinproteiner, cytotoksiner og fremgangsmater og anvendelser derav | |
| PH12012501006A1 (en) | Compositions and methods relating to anti-igf-1 receptor antibodies | |
| PE20091405A1 (es) | Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf | |
| EP2155874A4 (en) | FUSION PROTEINS OF COLLAGEN BINDING DOMAIN AND PARATHORMON | |
| MX2009013824A (es) | Proteinas de enlace de antigeno que enlazan par-2. | |
| ATE463512T1 (de) | Identifizierung und charakterisierung von funktionsblockierenden anti-ed-b-fibronektin antikörpern | |
| WO2012054321A3 (en) | Assays, methods and kits for predicting renal disease and personalized treatment strategies | |
| WO2015014794A8 (en) | Use of alpha-crystallin b (cryab) in the assessment of heart failure | |
| EP4566622A3 (en) | Dap10/dap12 fusion polypeptides | |
| WO2005074985A3 (en) | Methods of modulating cd200 and cd200r | |
| ATE370970T1 (de) | Antagonistische humane anti-hfas-ligand- antikörper und fragmente davon | |
| DE60322882D1 (de) | T zell-subpopulation zur regelung der darmimmunität |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |